Dr. Hoos on a Possible Successor Drug to Ipilimumab

Axel Hoos, MD, PhD
Published: Wednesday, Jun 22, 2011

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses the multiple immunotherapy agents in development, including the most advanced anti-PD-1 agent MDX-1106 which has a similar mechanism of action to ipilimumab (Yervoy).
SELECTED
LANGUAGE
Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses the multiple immunotherapy agents in development, including the most advanced anti-PD-1 agent MDX-1106 which has a similar mechanism of action to ipilimumab (Yervoy).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x